内源性大麻素系统调控治疗酒精使用障碍:临床前与人体研究的转化系统综述与荟萃分析
该系统综述与荟萃分析纳入63项临床前和人体研究,评估内源性大麻素系统调节剂对酒精使用障碍的作用。临床前荟萃分析显示CB-1R反向激动剂(SMD=-1.21)和大麻二酚(SMD=-0.70)减少酒精摄入,CB-1R激动剂增加摄入(SMD=+0.66)。人体研究结果不一致且总体无效,临床转化受安全性担忧和方法学异质性限制。
要点
- 临床前证据支持CB-1R反向激动剂和大麻二酚减少酒精摄入行为。
- CB-1R激动剂在临床前研究中增加酒精消耗。
- 人体研究结果不一致且总体无效,新型ECS调节剂研究不足。
核心结论
- 临床前证据支持内源性大麻素系统调控,尤其是CB-1R拮抗和大麻二酚,作为减少酒精使用行为的潜在策略。
- 临床转化受安全性担忧、方法学不一致和新型化合物研究不足的限制。
研究设计与样本
- 系统综述与荟萃分析,纳入63项临床前和人体研究,评估内源性大麻素系统调节剂对酒精使用障碍的作用。
- 临床前研究按作用机制综合,对CB-1R拮抗剂和反向激动剂、CB-1R激动剂及大麻二酚进行荟萃分析;人体研究因方法学异质性采用叙述性综合。
主要发现
- 临床前荟萃分析显示CB-1R反向激动剂减少酒精摄入(SMD=-1.21)。
- 临床前荟萃分析显示大麻二酚减少酒精摄入(SMD=-0.70)。
- 临床前荟萃分析显示CB-1R激动剂增加酒精消耗(SMD=+0.66)。
- 剂量反应分析发现CB-1R反向激动剂和大麻二酚存在非线性效应。
- 人体研究显示不一致且总体无效的结果,检查利莫那班或大麻二酚以外新型ECS调节剂的研究有限。
关键数值与推荐
- CB-1R反向激动剂减少酒精摄入的临床前合并效应量SMD=-1.21。
- 大麻二酚减少酒精摄入的临床前合并效应量SMD=-0.70。
- CB-1R激动剂增加酒精消耗的临床前合并效应量SMD=+0.66。
- 剂量反应分析识别CB-1R反向激动剂和大麻二酚的非线性效应。
临床怎么用
- 临床前证据提示CB-1R拮抗和大麻二酚可能减少酒精使用行为,但人体证据不一致且总体无效。
- 需开展基于机制的新型化合物(包括下一代CB-1R拮抗剂和大麻二酚)临床试验以桥接转化差距。
局限性
- 人体研究因方法学异质性仅作叙述性综合,未进行荟萃分析。
- 临床转化受安全性担忧和方法学不一致限制。
- 利莫那班或大麻二酚以外的新型ECS调节剂研究有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Alcohol use disorder (AUD) is a chronic condition with a staggering global burden and yet limited pharmacological treatments. Convergent evidence implicates the endocannabinoid system (ECS) as a potential therapeutic target due to its broad regulatory role across reward, stress, and affective processes. We conducted a systematic review and meta-analysis of 63 preclinical and human studies evaluating ECS modulators for AUD. Preclinical studies were synthesized by mechanism of action, and meta-analyses were conducted for cannabinoid receptor (CB-1R) antagonists and inverse agonists, CB-1R agonists, and cannabidiol (CBD). Human studies were narratively synthesized due to methodological heterogeneity. Preclinical data meta-analyses demonstrated that CB-1R inverse agonists (SMD = -1.21) and CBD (SMD = -0.70) reduced alcohol intake, while CB-1R agonists increased consumption (SMD = +0.66). Dose-response analyses identified non-linear effects for CB-1R inverse agonists and CBD. In contrast, human studies showed inconsistent and generally null effects, with limited studies examining newer ECS modulators beyond rimonabant or CBD. While preclinical evidence supports ECS modulation, particularly CB-1R antagonism and CBD, as promising strategies for reducing alcohol use behaviors, clinical translation has been limited by safety concerns, methodological inconsistencies, and under-investigation of novel compounds. Mechanistically informed trials of novel compounds, including next-generation CB-1R antagonists and CBD, are needed to bridge this translational gap and yield new treatments for AUD.
引用
- Costa GPA, Cerezo-Matias MA, Funaro MC, et al. Modulating the endocannabinoid system in alcohol use disorder: A translational systematic review and meta-analysis of preclinical and human studies. Mol Psychiatry. 2026. PMID: 41760917. doi:10.1038/s41380-026-03523-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。